Neurocrine Biosciences Provides Development Pipeline Update

Uncategorized
November 9, 2023
img: Featured

Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency Phase 2 Proof-of-Concept Study of NBI-1065846 in Patients with Anhedonia in Major Depressive Disorder Failed to Meet its Primary Endpoint SAN DIEGO ,

Uncategorized